Structure Therapeutics reports promising results for weight-loss pill

December 18, 2023 08:56 AM PST | By Invezz
 Structure Therapeutics reports promising results for weight-loss pill
Image source: Invezz

Structure Therapeutics Inc (NASDAQ:GPCR) says its experimental weight-loss pill showed promising results in a mid-stage trial. Its shares are still down more than 40% at writing.

GSBR-1290 is statistically better than placebo

GSBR-1290 helped participants lose 4.74% of their body weight in eight weeks, as per a press release on Monday.

The results were statistically better than a placebo. According to Raymond Stevens – the Chief Executive of Structure Therapeutics:

Our data demonstrated that once-daily GSBR-1290 has potential to be a best-in-class compound and a backbone for future combinations that could address large cardiometabolic indications.

The GLP-1 receptor antagonist also resulted in a clinically meaningful decrease in blood sugar level after twelve weeks, as per the preliminary data reported today. Structure Therapeutics stock is now down 55% versus its year-to-date high.

Why is Structure Therapeutics stock down today?

Shares of Structure Therapeutics are taking a beating this morning primarily because the GSBR-1290 failed to be as effective in reducing weight as a competing, under-development pill by Eli Lilly.  

The investigational drug has to deliver over 7.0% loss in body weight after twelve weeks to be categorized as the “best in class”, analysts at Jefferies told clients in a research note late last month.

The mid-stage data that the pharmaceutical firm announced today did confirm its weight-loss pill to have a tolerability advantage, though. $GPCR will report the post twelve weeks data for GSBR-1290 in Q2 of the coming year.

In November, the Nasdaq-listed company reported a near $24 million net loss for the three-month period through September 30th. Heading into Monday, Wall Street had a consensus “buy” rating on Structure Therapeutics stock.

The post Structure Therapeutics reports promising results for weight-loss pill appeared first on Invezz


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next